Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × Afatinib × Clear all

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Phase 2 Terminated

Neoplasms, Prostatic Neoplasms

NCT00706628 2015-01-15

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Phase 2 Completed

87 enrolled 20 charts

Prostatic Neoplasms